Analyzing Oxford BioMedica (OTCMKTS:OXBDF) and Adlai Nortye (NASDAQ:ANL)

Adlai Nortye (NASDAQ:ANL) and Oxford BioMedica (OTCMKTS:OXBDF) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

Institutional & Insider Ownership

35.2% of Adlai Nortye shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Adlai Nortye and Oxford BioMedica”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5.00 million	104.72	-$35.53 million	N/A	N/A
Oxford BioMedica	$164.59 million	4.73	-$46.74 million	N/A	N/A

Adlai Nortye has higher earnings, but lower revenue than Oxford BioMedica.

Analyst Recommendations

This is a summary of recent ratings and price targets for Adlai Nortye and Oxford BioMedica, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1	0	5	0	2.67
Oxford BioMedica	0	1	0	0	2.00

Adlai Nortye currently has a consensus target price of $24.25, indicating a potential upside of 85.26%. Given Adlai Nortye’s stronger consensus rating and higher possible upside, equities analysts clearly believe Adlai Nortye is more favorable than Oxford BioMedica.

Profitability

This table compares Adlai Nortye and Oxford BioMedica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Oxford BioMedica	N/A	N/A	N/A

Risk and Volatility

Adlai Nortye has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Oxford BioMedica has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

Summary

Adlai Nortye beats Oxford BioMedica on 6 of the 8 factors compared between the two stocks.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

About Oxford BioMedica

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.